NOVARTIS AG NAMENS-AKTIEN SF 0,5
NOVARTIS AG NAMENS-AKTIEN SF 0,5/ CH0012005267 /
904278
|
26/09/2024 14:20:12
|
Diferencia
-1.160
|
Volumen |
Bid14:20:12 |
Ask14:20:12 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
102.940EUR
|
-1.11%
|
-
Volumen de negocios: - |
102.940Volumen de oferta: - |
103.280Tamaño/ Volumen/ Formato de Ask: - |
234.89 mil millonesEUR |
- |
- |
Descripción de negocio
Novartis provides innovative healthcare solutions that address the evolving needs of patients and societies. Headquartered in Basel, Switzerland, Novartis offers a diversified portfolio to best meet these needs: innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis has leading positions globally in each of these areas. Novartis products are sold in approximately 155 countries around the world.
Consejo de gestión & Consejo de supervisión
| CEO |
| Vasant Narasimhan, M.D. |
| Consejo de gestión |
| Harry Kirsch, Dr. Klaus Moosmayer, Dr. Steffen Lang, Karen L. Hale, Rob Kowalski, Shreeram Aradhye, Victor Bulto, Aharon (Ronny) Gal, Dr. Fiona H. Marshall, Patrick Horber |
| Consejo de supervisión |
| Dr. Joerg Reinhardt, Bridgette Heller, Charles L. Sawyers, M.D., Dr. Charlotte Pamer-Wieser, Dr. Nancy C. Andrews, Elizabeth Doherty, Frans van Houten, Simon Moroney, Ton Buechner, William T. Winters, Daniel Hochstrasser, Ana de Pro Gonzalo, John D. Young, Patrice Bula |
Datos de la empresa
| Nombre: |
Novartis AG |
| Dirección: |
Lichtstrasse 35,CH-4002 Basel |
| Teléfono: |
+41-61-324-1111 |
| Fax: |
+41-61-324-8001 |
| E-mail: |
-
|
| Internet: |
www.novartis.com |
| Industria: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Subsector: |
Pharmaceuticals |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
86.85% |
| Fecha de OPI: |
07/03/1996 |
Calendario de la empresa
|
CW 44 | 29/10/2024
Interim Report 3rd Quarter/9 Months
|
